MX2023009650A - Nuevas particulas viricas con fines terapeuticos. - Google Patents
Nuevas particulas viricas con fines terapeuticos.Info
- Publication number
- MX2023009650A MX2023009650A MX2023009650A MX2023009650A MX2023009650A MX 2023009650 A MX2023009650 A MX 2023009650A MX 2023009650 A MX2023009650 A MX 2023009650A MX 2023009650 A MX2023009650 A MX 2023009650A MX 2023009650 A MX2023009650 A MX 2023009650A
- Authority
- MX
- Mexico
- Prior art keywords
- virus particles
- lcmv
- segment
- therapeutic purposes
- virus
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 5
- 239000002245 particle Substances 0.000 title abstract 5
- 230000001225 therapeutic effect Effects 0.000 title 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 abstract 5
- 108700026244 Open Reading Frames Proteins 0.000 abstract 2
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 abstract 1
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10061—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21159746 | 2021-02-26 | ||
| PCT/EP2022/054766 WO2022180203A1 (en) | 2021-02-26 | 2022-02-25 | New virus particles for therapeutic purposes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009650A true MX2023009650A (es) | 2023-08-24 |
Family
ID=74844711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009650A MX2023009650A (es) | 2021-02-26 | 2022-02-25 | Nuevas particulas viricas con fines terapeuticos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220273741A1 (enExample) |
| EP (1) | EP4297763A1 (enExample) |
| JP (1) | JP2024508823A (enExample) |
| KR (1) | KR20230153411A (enExample) |
| CN (1) | CN117241812A (enExample) |
| AU (1) | AU2022226407A1 (enExample) |
| CA (1) | CA3208055A1 (enExample) |
| CL (1) | CL2023002508A1 (enExample) |
| IL (1) | IL305349A (enExample) |
| MX (1) | MX2023009650A (enExample) |
| WO (1) | WO2022180203A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025046106A1 (en) | 2023-08-31 | 2025-03-06 | Abalos Therapeutics Gmbh | Virus particles with improved entry into tumor cells |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004034461B4 (de) * | 2004-07-16 | 2008-02-07 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren |
| DE102015207036A1 (de) | 2015-04-17 | 2016-10-20 | Karl Sebastian Lang | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
| EP3373959B1 (en) * | 2015-11-12 | 2022-06-29 | Hookipa Biotech GmbH | Arenavirus particles as cancer vaccines |
| DE102018215551A1 (de) * | 2018-09-12 | 2020-03-12 | Virolutions Biotech Gmbh | Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten |
-
2022
- 2022-02-25 JP JP2023551984A patent/JP2024508823A/ja active Pending
- 2022-02-25 CN CN202280030958.8A patent/CN117241812A/zh active Pending
- 2022-02-25 CA CA3208055A patent/CA3208055A1/en active Pending
- 2022-02-25 AU AU2022226407A patent/AU2022226407A1/en active Pending
- 2022-02-25 US US17/680,960 patent/US20220273741A1/en active Pending
- 2022-02-25 KR KR1020237032657A patent/KR20230153411A/ko active Pending
- 2022-02-25 EP EP22711182.0A patent/EP4297763A1/en active Pending
- 2022-02-25 IL IL305349A patent/IL305349A/en unknown
- 2022-02-25 MX MX2023009650A patent/MX2023009650A/es unknown
- 2022-02-25 WO PCT/EP2022/054766 patent/WO2022180203A1/en not_active Ceased
-
2023
- 2023-08-24 CL CL2023002508A patent/CL2023002508A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022180203A1 (en) | 2022-09-01 |
| EP4297763A1 (en) | 2024-01-03 |
| US20220273741A1 (en) | 2022-09-01 |
| CA3208055A1 (en) | 2022-09-01 |
| CL2023002508A1 (es) | 2024-01-26 |
| AU2022226407A9 (en) | 2024-01-25 |
| CN117241812A (zh) | 2023-12-15 |
| JP2024508823A (ja) | 2024-02-28 |
| IL305349A (en) | 2023-10-01 |
| KR20230153411A (ko) | 2023-11-06 |
| AU2022226407A1 (en) | 2023-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kis et al. | Emerging technologies for low‐cost, rapid vaccine manufacture | |
| Lundstrom | Replicon RNA viral vectors as vaccines | |
| JP2013511272A5 (enExample) | ||
| ZA202100386B (en) | Influenza virus hemagglutinin mutants | |
| PH12017501836A1 (en) | Production of oversized adeno-associated vectors | |
| MX2022010175A (es) | Proteinas de union a flt3 y metodos de uso. | |
| ZA202304098B (en) | Il-2 mutants and application thereof | |
| JP2010526546A (ja) | ワクシニアウイルス系及び組換えワクシニアウイルス系ワクチンの精製 | |
| ATE384785T1 (de) | Herstellung von viren, virusisolaten, und impfstoffen | |
| EP4249064A3 (en) | Novel fusion protein specific for cd137 and pd-l1 | |
| WO2022256498A9 (en) | Msln targeting trispecific proteins and methods of use | |
| MX2015007093A (es) | Composiciones y metodos para el tratamiento de canceres cerebrales. | |
| PH12021552577A1 (en) | Engineered producer cell lines and methods of making and using the same | |
| Ruocco et al. | Transient expression of glycosylated SARS-CoV-2 antigens in Nicotiana benthamiana | |
| WO2021211885A8 (en) | Matrix bound vesicles (mbv) for treatment of acute respiratory distress syndrome | |
| MX2024005414A (es) | Particulas de arenavirus modificadas que expresan kras mutante, el gen conductor del cancer mutado o antigeno asociado al tumor como inmunoterapias contra el cancer. | |
| CL2023002508A1 (es) | Nuevas partículas víricas con fines terapéuticos | |
| Keresztes et al. | The highly productive thermothelomyces heterothallica C1 expression system as a host for rapid development of influenza vaccines | |
| Yiang et al. | Endoplasmic reticulum stress in elderly patients with COVID-19: potential of melatonin treatment | |
| WO2023023597A8 (en) | Virus-like particle | |
| MX2025002401A (es) | Composiciones veterinarias de particulas similares a virus modificadas de cmv y antigenos de ngf | |
| WO2022236276A3 (en) | Anti-tigit antibodies, anti-cd96 antibodies, and methods of use thereof | |
| Cash et al. | The effects of glycosylation inhibitors on the maturation and intracellular polypeptide synthesis induced by snowshoe hare bunyavirus | |
| ATE480630T1 (de) | Methode zur herstellung von viralen partikeln welche eine veränderte zellbindungsaktivität haben und deren verwendungen | |
| SA522441579B1 (ar) | ترميز الفيروس الربدي ناتج عودة الارتباط الجيني لبروتين دمج شظية قابلة للتبلر لنطاق عنقود التمايز 80 خارج الخلايا |